Recommendation of the President – Kuvan (sapropterin dihydrochloride)
On 9 August 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 86/2024 on the appropriateness of granting approval for the reimbursement of the medicinal product Kuvan (sapropterin dihydrochloride) for the indications: atypical form of phenylketonuria – biopterin synthase defect, 6-pyruvyltetrahydrobiopterin synthase (6-PTPS) defect, guanosine triphosphate cyclohydrolase (GTP-CH) deficiency